Literature DB >> 28240793

Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia.

Michele P Lambert1,2, Char M Witmer1,2, Janet L Kwiatkowski1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28240793     DOI： 10.1002/ajh.24705

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  10 in total

Review 1.  Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice.

Authors:  Cindy E Neunert; Melissa J Rose
Journal:  Blood Adv       Date:  2019-06-25

Review 2.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 3.  Activity of eltrombopag in severe aplastic anemia.

Authors:  Phillip Scheinberg
Journal:  Blood Adv       Date:  2018-11-13

4.  Eltrombopag mobilizes iron in patients with aplastic anemia.

Authors:  Zhen Zhao; Qian Sun; Lori J Sokoll; Michael Streiff; Zhe Cheng; Sophie Grasmeder; Danielle M Townsley; Neal S Young; Cynthia E Dunbar; Thomas Winkler
Journal:  Blood       Date:  2018-04-09       Impact factor: 22.113

5.  The child with immune thrombocytopenia: to treat or not to treat, is that still the question?

Authors:  Nichola Cooper; Douglas B Cines
Journal:  Haematologica       Date:  2019-11       Impact factor: 9.941

6.  Long-term eltrombopag for bone marrow failure depletes iron.

Authors:  David J Young; Xing Fan; Emma M Groarke; Bhavisha Patel; Ronan Desmond; Thomas Winkler; Andre Larochelle; Katherine R Calvo; Neal S Young; Cynthia E Dunbar
Journal:  Am J Hematol       Date:  2022-03-26       Impact factor: 13.265

7.  Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.

Authors:  Francesca Punzo; Chiara Tortora; Maura Argenziano; Maddalena Casale; Silverio Perrotta; Francesca Rossi
Journal:  PLoS One       Date:  2018-12-03       Impact factor: 3.240

8.  Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.

Authors:  Zhi-Jian Liu; Emoke Deschmann; Haley E Ramsey; Henry A Feldman; Bethan Psaila; Nichola Cooper; Evangelia Vlachodimitropoulou; John Porter; James Bussel; Michael Georgieff; Martha Sola-Visner
Journal:  Blood Adv       Date:  2022-01-11

9.  Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.

Authors:  Marta Bortolotti; Loredana Pettine; Anna Zaninoni; Giorgio Alberto Croci; Wilma Barcellini; Bruno Fattizzo
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-30

10.  Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Authors:  Ayça Koca Yozgat; Göksel Leblebisatan; Sinan Akbayram; Simge Çınar Özel; Zeynep Karakaş; Erol Erduran; Şebnem Yılmaz; Ülker Koçak; Şule Ünal; Gül Nihal Özdemir; Meryem Albayrak; Emine Zengin; Yeşim Oymak; Özcan Bör; Hasan Fatih Çakmaklı; Murat Söker; Dilek Gürlek Gökçebay; Hüseyin Tokgöz; Barış Malbora; Serap Karaman; Tiraje Celkan; İlgen Şaşmaz; Neşe Yaralı; Hale Ören; Ayşegül Ünüvar; Namık Yaşar Özbek
Journal:  Turk J Haematol       Date:  2020-03-17       Impact factor: 1.831
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.